Evinacumab Cuts LDL-C in Children With Homozygous Familial Hypercholesterolemia

Positive results were announced from a phase 3 trial evaluating evinacumab in children 5 to 11 years with HoFH.

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,M Doortje Reijman , ,Research Associate In Pediatric Metabolic Diseases ,Amsterdam University Medical Center ,Drug Administration ,Research Associate ,Pediatric Metabolic Diseases ,Amsterdam University Medical ,